1. Home
  2. ALMS
  3. ALMS News

Latest ALUMIS INC (ALMS) News on November 22, 2024

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
ALMS

GlobeNewswire

7 days ago

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
ALMS

GlobeNewswire

8 days ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
ALMS

GlobeNewswire

18 days ago

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
ALMS

GlobeNewswire

2 months ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis to Participate in Upcoming September Investor Conferences
ALMS

GlobeNewswire

3 months ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
ALMS

GlobeNewswire

3 months ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
ALMS

GlobeNewswire

4 months ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Share on Social Networks: